Hamid Emamekhoo, MD, of the University of Wisconsin School of Medicine and Public Health, Madison, WI, discusses the CHECKMATE 920 (NCT02982954) study investigating the safety of nivolumab in combination with ipilimumab in subjects with previously untreated advanced or metastatic renal cell cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
